In CSPG4.CART-treated mdx mice, Adgre1 expression was significantly reduced, and Il-1β showed a slight, though not significant, decrease, suggesting that this adoptive T cell therapy may help reshape the immune landscape in DMD, particularly by modulating macrophage activity. The gene discussed is ADGRE1; the disease is Duchenne muscular dystrophy.